(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Extensive-Stage Small Cell Lung Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ Extensive-Stage Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Extensive-Stage Small Cell Lung Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Extensive-Stage Small Cell Lung Cancer Market.
The Extensive-Stage Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Extensive-Stage Small Cell Lung Cancer Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Extensive-Stage Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.
-
Extensive-Stage Small Cell Lung Cancer companies working in the treatment market are Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, BioNTech, Imago BioSciences, Akeso, Qilu Pharmaceutical Co, Amgen, Sorrento Therapeutics, BeiGen, and others, are developing therapies for the Extensive-Stage Small Cell Lung Cancer treatment
-
Emerging Extensive-Stage Small Cell Lung Cancer therapies in the different phases of clinical trials are- RP12146, SYHA1807, BNT411, Bomedemstat, AK104, QL1706, Tarlatamab, Socazolimab, Tislelizumab, and others are expected to have a significant impact on the Extensive-Stage Small Cell Lung Cancer market in the coming years.
-
In January 2025, Asher Biotherapeutics, a biotechnology company focused on developing precisely-targeted immunotherapies for cancer and infectious diseases, announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ: AMGN). The collaboration will evaluate etakafusp alfa (formerly known as AB248), Asher Bio’s investigational CD8+ T cell-targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA® (tarlatamab), Amgen’s DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy, in patients with extensive-stage small cell lung cancer (ES-SCLC).
-
In December 2024, Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company dedicated to developing transformative therapies for cancer and diabetes patients, has announced the completion of the Phase 1 dose escalation phase of the Acclaim-3 clinical trial. This trial evaluates Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). Additionally, the Safety Review Committee (SRC) has approved the initiation of the Phase 2 expansion phase of the trial.
-
In December 2024, AstraZeneca’s IMFINZI® (durvalumab) has received approval in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose condition has not worsened after receiving concurrent platinum-based chemotherapy and radiation therapy
-
In May 2024, Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for IMDELLTRA™ (tarlatamab-dlle) to treat adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following platinum-based chemotherapy. This approval was expedited due to the promising response rate and duration of response (DoR) seen in clinical trials. Ongoing approval for this use may depend on further confirmation of clinical benefits in subsequent confirmatory trials.
-
In May 2024, Genprex, Inc. has announced that the first patient with extensive-stage small cell lung cancer (ES-SCLC) has begun treatment with a combination of quaratusugene ozeplasmid (Reqorsa) and atezolizumab (Tecentriq) in the phase 1, dose-escalation part of the Acclaim-3 trial (NCT05703971). Acclaim-3 is an open-label, dose-escalation, phase 1/2 study designed to evaluate the clinical response of maintenance therapy using quaratusugene ozeplasmid alongside atezolizumab in patients with ES-SCLC.
Extensive-Stage Small Cell Lung Cancer Overview
Extensive-Stage Small Cell Lung Cancer (ESCLC) is a classification of small cell lung cancer (SCLC), which is a fast-growing type of lung cancer typically associated with heavy smoking. SCLC is divided into two stages: limited stage and extensive stage.
Get a Free Sample PDF Report to know more about Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight
Emerging Extensive-Stage Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:
-
RP12146: Rhizen Pharmaceuticals
-
SYHA1807: CSPC ZhongQi Pharmaceutical Technology
-
BNT411: BioNTech
-
Bomedemstat: Imago BioSciences
-
AK104: Akeso
-
QL1706: Qilu Pharmaceutical Co
-
Tarlatamab: Amgen
-
Socazolimab: Sorrento Therapeutics
-
Tislelizumab: BeiGen
Extensive-Stage Small Cell Lung Cancer Route of Administration
Extensive-Stage Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Intravenous
-
Subcutaneous
-
Parenteral
-
Topical
Extensive-Stage Small Cell Lung Cancer Molecule Type
Extensive-Stage Small Cell Lung Cancer Products have been categorized under various Molecule types, such as
Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment
-
Extensive-Stage Small Cell Lung Cancer Assessment by Product Type
-
Extensive-Stage Small Cell Lung Cancer By Stage and Product Type
-
Extensive-Stage Small Cell Lung Cancer Assessment by Route of Administration
-
Extensive-Stage Small Cell Lung Cancer By Stage and Route of Administration
-
Extensive-Stage Small Cell Lung Cancer Assessment by Molecule Type
-
Extensive-Stage Small Cell Lung Cancer by Stage and Molecule Type
DelveInsight’s Extensive-Stage Small Cell Lung Cancer Report covers around 30+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Extensive-Stage Small Cell Lung Cancer product details are provided in the report. Download the Extensive-Stage Small Cell Lung Cancer pipeline report to learn more about the emerging Extensive-Stage Small Cell Lung Cancer therapies
Extensive-Stage Small Cell Lung Cancer Pipeline Analysis:
The Extensive-Stage Small Cell Lung Cancer pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Extensive-Stage Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Extensive-Stage Small Cell Lung Cancer Treatment.
-
Extensive-Stage Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Extensive-Stage Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Extensive-Stage Small Cell Lung Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Extensive-Stage Small Cell Lung Cancer drugs and therapies
Extensive-Stage Small Cell Lung Cancer Pipeline Market Drivers
Extensive-Stage Small Cell Lung Cancer Pipeline Market Barriers
-
However, high cost of the treatment, lack of awareness among the people for early detection of cancer and other factors are creating obstacles in the Extensive-Stage Small Cell Lung Cancer Market growth.
Scope of Extensive-Stage Small Cell Lung Cancer Pipeline Drug Insight
-
Coverage: Global
-
Key Extensive-Stage Small Cell Lung Cancer Companies: Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, BioNTech, Imago BioSciences, Akeso, Qilu Pharmaceutical Co, Amgen, Sorrento Therapeutics, BeiGen, and others
-
Key Extensive-Stage Small Cell Lung Cancer Therapies: RP12146, SYHA1807, BNT411, Bomedemstat, AK104, QL1706, Tarlatamab, Socazolimab, Tislelizumab, and others
-
Extensive-Stage Small Cell Lung Cancer Therapeutic Assessment: Extensive-Stage Small Cell Lung Cancer current marketed and Extensive-Stage Small Cell Lung Cancer emerging therapies
-
Extensive-Stage Small Cell Lung Cancer Market Dynamics: Extensive-Stage Small Cell Lung Cancer market drivers and Extensive-Stage Small Cell Lung Cancer market barriers
Request for Sample PDF Report for Extensive-Stage Small Cell Lung Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Extensive-Stage Small Cell Lung Cancer Report Introduction
2. Extensive-Stage Small Cell Lung Cancer Executive Summary
3. Extensive-Stage Small Cell Lung Cancer Overview
4. Extensive-Stage Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment
5. Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutics
6. Extensive-Stage Small Cell Lung Cancer Late Stage Products (Phase II/III)
7. Extensive-Stage Small Cell Lung Cancer Mid Stage Products (Phase II)
8. Extensive-Stage Small Cell Lung Cancer Early Stage Products (Phase I)
9. Extensive-Stage Small Cell Lung Cancer Preclinical Stage Products
10. Extensive-Stage Small Cell Lung Cancer Therapeutics Assessment
11. Extensive-Stage Small Cell Lung Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Extensive-Stage Small Cell Lung Cancer Key Companies
14. Extensive-Stage Small Cell Lung Cancer Key Products
15. Extensive-Stage Small Cell Lung Cancer Unmet Needs
16 . Extensive-Stage Small Cell Lung Cancer Market Drivers and Barriers
17. Extensive-Stage Small Cell Lung Cancer Future Perspectives and Conclusion
18. Extensive-Stage Small Cell Lung Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Extensive-Stage SCLC Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | CSPC ZhongQi Pharma, BioNTech, Imago BioSciences, Akeso, Qilu
